Publications by authors named "Matthew Scaramozza"

Claim this Profile
C
Characterizing gait in people with multiple sclerosis using digital data from smartphone sensors: A proposed framework.
Angelos Karatsidis, Lorenza Angelini, Matthew Scaramozza, Emmanuel Bartholome, Susanne P Clinch

Mult Scler· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM Study.
Krupa Shah Pandey, Kathryn Giles, Konstantin Balashov, Richard Macdonell, Jörg Windsheimer, Matthew Scaramozza

Neurol Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study.
Samuel F Hunter, John W Lindsey, Benjamin Osborne, Bethany Schreiber, Filipe Branco, Matthew Scaramozza

Mult Scler Relat Disord· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensor-Derived Measures of Motor and Cognitive Functions in People With Multiple Sclerosis Using Unsupervised Smartphone-Based Assessments: Proof-of-Concept Study.
Matthew Scaramozza, Aurélie Ruet, Patrizia A Chiesa, Laïtissia Ahamada, Emmanuel Bartholomé

JMIR Form Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study.
James D Bowen, Jessica Stulc, Samuel F Hunter, Hailu Chen, James B Lewin, Matthew Scaramozza

Adv Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Konectom™ cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measure.
Matthew Scaramozza, Patrizia A Chiesa, Lauren Zajac, Zhaonan Sun, Minao Tang

Mult Scler· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.
Barry A Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Matthew Scaramozza

Neurol Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Barry A Singer, Douglas L Arnold, Jelena Drulovic, Mark S Freedman, Ralf Gold, Matthew Scaramozza

Mult Scler· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial.
Patrick Vermersch, Matthew Scaramozza, Seth Levin, Raed Alroughani, Kumaran Deiva

JAMA Netw Open· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic lesion activity and disability progression in secondary progressive multiple sclerosis.
Vanessa Beynon, Ilena C George, Colm Elliott, Douglas L Arnold, Jun Ke, Matthew Scaramozza

BMJ Neurol Open· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells.
Eris Bame, Hao Tang, Jeremy C Burns, Million Arefayene, Klaus Michelsen, Matthew Scaramozza

Clin Transl Immunology· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study.
Ravi Shankar P Singh, Vivek Pradhan, Erika S Roberts, Matthew Scaramozza, Elizabeth Kieras

Clin Transl Sci· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study.
Christopher Tehlirian, Elena Peeva, Elizabeth Kieras, Matthew Scaramozza, Erika S Roberts

Lancet Rheumatol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
Karen M Page, Mayte Suarez-Farinas, Maria Suprun, Weidong Zhang, Sandra Garcet, Matthew Scaramozza

J Invest Dermatol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
Christopher Banfield, Matthew Scaramozza, Weidong Zhang, Elizabeth Kieras, Karen M Page

J Clin Pharmacol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Thomas P Leist, Giancarlo Comi, Bruce A C Cree, Patricia K Coyle, Mark S Freedman, Matthew Scaramozza

Lancet Neurol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
Giancarlo Comi, Hans-Peter Hartung, Nuwan C Kurukulasuriya, Steven J Greenberg, Matthew Scaramozza

Expert Opin Pharmacother· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reward circuitry in resilience to severe trauma: an fMRI investigation of resilient special forces soldiers.
Meena Vythilingam, Eric E Nelson, Matthew Scaramozza, Tracy Waldeck, Gary Hazlett

Psychiatry Res· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis